AIM ImmunoTech Inc AIM

ASE: AIM | ISIN: US00901B1052   31/05/2024
0,362 USD (-0,28%)
(-0,28%)   31/05/2024

9 mei 2024 · AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast · Persbericht

6 mei 2024 · AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® · Persbericht

29 april 2024 · AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer · Persbericht

10 april 2024 · AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer · Persbericht

2 april 2024 · AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update · Persbericht

26 maart 2024 · AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast · Persbericht

25 maart 2024 · AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research · Persbericht

7 maart 2024 · AIM ImmunoTech Announces Launch of CEO Corner Platform · Persbericht

29 februari 2024 · AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update · Persbericht

14 februari 2024 · AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer · Persbericht

24 januari 2024 · AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer · Persbericht

22 januari 2024 · AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer · Persbericht

10 januari 2024 · AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer · Persbericht

27 november 2023 · AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents · Persbericht

15 november 2023 · AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update · Persbericht

9 november 2023 · AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast · Persbericht

17 oktober 2023 · AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs · Persbericht

11 september 2023 · AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer · Persbericht

15 augustus 2023 · AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update · Persbericht

9 augustus 2023 · AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast · Persbericht

Mijn selecties